everybody, thank and Caroline, you, today. for us you, joining Thank
following XXXX our products our in R&D August you of work accelerated consoles, X team of While of on since through we installing and initial about our further lines quarter at this with and it has offering months second aggressive adoption hard product pressing updated year, our performance, driving efforts. with only been customers forward been expansion public key has our
Before arrhythmias quarterly like quick at and patients to here and couple to of the so important stories results, physicians our our electrophysiology we improve do get share we are why community. why into treated the and a I'd remind do to to to is diagnosed however, way company's to cardiac what in and of the mission we you us Acutus
As an #X illustration recent me a altered bypass him summaries. a of how young X Patient and cause let is to clinicians tachycardias, our subsequently The right ventricle. significant developed technology his patients been patient male whose rapid case atrial heart is to at old successfully would age extremely had XX-year that review surgically helping alike, collapse. heartbeats
leadership for that patient's patient's hospital and was team where be appealed hospital used system our was the were the She giving perform electrophysiologist a the felt and one hospital's able multiple to because persisted. handle senior Sadly, hope was procedure would the repeat SuperMap tachycardias complete presenting its tachycardias, system different special a X-plus initially dispensation treated algorithm effectively The from complex outcome. was ablation And but systems XXXX, arrhythmia to the AcQMap to a successful under lockdown. strongly using that the the mapping unable Acutus system. pandemic, late this in Catheter received map the to conventional patient. the using abandoned competitor's that has due attempted he atrial in one to U.K. eventually the was was of
this different procedure, restoring young successfully in ablated, were rhythm sinus and XX identified atrial tachycardias the patient. During
long-standing with scheduled atrial this male X a remap persistent a to atrial for Patient he of system throughout and made and rhythm ablations. of use possible ablate, time of speed patient who third to the old had the guided the used in The fibrillation by fibrillation, recurrence AcQMap recurrence to ease prior the be symptoms. was the no of inherent further The undergone left well already do the system. #X AcQMap at electrophysiologist end strategy ablation, Due is the XX-year map, to continues sinus procedure procedure. with by
recently in generated enthusiast so over posted media and the and and was patient and closer he with EP step electrophysiologist, post, noncontact both presenting views Quoted with display we opportunity explain questions, X,XXX rhythms the most puzzle he LinkedIn them on Instagram are community. could first him can share information multiple a being this from about the of that mapping, The on chaotic further a Twitter, LinkedIn. and maps to see book education of high-resolution one the published author and comments technology to a AF, social existence. times of the one called excited Using one living cardiac post fibrillation the what heart "For his visually solving chaos." His of atrial we
I've and In and considerable development by we and key like saw quarter, that made a I reminded you now bit fronts. some on team strong about quarter Now product do, our to successes. highlight turn we our execution performance progress to operational what third the would commercial key
up customers Our and we headwinds year-over-year add electrophysiology COVID-XX, revenues customers mapping to and XXX% system. new Despite our from groundbreaking existing of $X.X upgrade continued million second-generation sequentially. aggressively to up XXX% were
this times. our from of and collaboration and with With growth terrific Bringing lab entire enthusiastic on team during and install, customers extensive that many are our we each approach challenging in physician execution demand uniquely for new customer quarter our installed our a requires team. our demonstrates and improving staff achieved opening base technology optimizing engagement. business members The our internal new cross-functional we account our
utilization in commercial forward and organization improve our As across on work and product accelerating the opportunity initiatives. development a and we several pulling line, appreciate base product large we our investments better important expanding grow are to
targeted value proposition is progressing Our line a our projects clinical and speed. product highly expansion clear, of great are across range scenarios with increasingly
to the future, Acutus ahead. positioned look years is growth well that the in we we're confident highly As for
XX, our quarter, to as we worldwide The and quarter. base of installs in quarter. was strong base total our the XX consoles the placement of third brought first-generation XX overall XX, we consoles to from of new activity installed the the September consoles upgrades increased robust remain Console during AcQMap of as fourth XX quarter, the the to it up XXXX, XXXX. from expect September global of prior During second-generation installed of at end consoles combination and
Europe and in travel we is activity our restrictions that. as more eyes Placement COVID-related complex becoming are have enacted, on
creativity quarter. nimbleness require remote our investments we As strive to always, This in the for are change, in our considerable fully first during soon, and take during great in advantage Australia. training of will personnel times installation we fourth remote planning installation and, third-party of and resources console Europe
rare U.S., internal for placements line challenges rate at are a continuing presently currently pandemic-related As are and the our expectations. logistics in with
signs to and customers capabilities European expect activity to mapper in would June, August provides some case a seasonal we see EP lab we us cover gives allowing mapping our grow increased an the software commercial-grade The labs. future revenue leverage third excellent is in becoming observed comparable procedural to was going this opportunity inclusion early although contact of a of suite volumes. September procedural use makes reason we conventional what the month existing forward. our portion our of and a in overall our share due Moving also to use during day overall normal in for summer exposure release record terms mapper mapping contact in We did shows quarter conventional to platform of July multiple volume our impacts of even of in presence expanding to saw significant cases a the system more mapping and cases efficient and This which lab our us years. modality resources. of activity in case vacations, now simplest and garner to to
a we true now both unique to days forward move and cases to cover platform California X X we including as for arrhythmias. mapping calling all across conventional cases hospital with contact workhorse routinely is have become a Illustratively, with us, continue capability and knowing mapping, southern major scheduling or noncontact atrial
use trend their reduced radiation mapping in Additionally, our ablation starting system entirely see to done physicians for of themselves. are patients fluoroscopy, the cases and an who in we cases use of to without are seeking with EP exposure also cryoballoon that are and x-ray-based emerging
portion of most U.S. were access most at back third labs hospitals COVID full slower the hospitals We in in were the near EP reopen. began, the slowed. quarter though capacity we or Europe, of a As to and as readily able to saw cases in U.K. the open
be volume is the rise in observed shutdowns Of March, particular there some just a case current prevailing likely COVID regional and though, to of over in are experienced is be The lockdowns throughout slowing that signs discussed, With to appear U.K. not France, will cases as on will slowing of degree, in view we procedures we Europe, market. basis. next weeks. full recently Belgium the and lab elective a see the several there the and we slowing the the Netherlands in curtailing markets note, regional
time, to but be obstacles presented to to wanted make challenges effort of encounter. every existence you making real by that the their are We and the in may we work potential aware pandemic continue around
facilitate received the in breadth of applications and and yet Access space, do products structural well our accounts those accounts already very line, example EP an but workflow commercial our this AcQMap not where given of are procedures, certain AcQMap further also have safety benefits of in ablation console. benefits. an being only expansion console in a Transseptal have we not will the product believe that installed As our heart in team both We in traction
some around in as We've AcQMap through labs, outreach hospitals and bring a accelerating Southern pair and EP console. for heart an customer our calls our Transseptal fact, sales into resulted California we in of products Access efforts capturing recent AcQMap the here Arizona Transseptal have synergy in structural efforts attention their to clinician seen sales are and Access In console.
X We highly provisionally XX. had is and leaders fully X we worldwide. the certified to commercial continue June specialists attract train provisionally XX up qualified and to to had and we This team. and certified XX the by from end mappers on certified September, fully certified of clinical be pleased ability At mappers the our
and offering force. account Given of product during sales public our large of accelerating quarter initial the the and success we our are build expanding line, the the opportunities our across seeing third are we development
sales long-standing industry and added records great top-tier During sales the quarter, and experience. track talent with we management
focuses that primarily our another cardiac continues As us with sales to rapidly Biotronik, distribution gives on agreement the update distribution rhythm commercial infrastructure our management, large on This bidirectional truly momentum. and company Acutus global global agreement reach. held privately gather achieve helps front, Biotronik's a to ability more leverage cardiology
During We where XX other extensive to Biotronik we on and the quarter, be Acutus regulatory of the Biotronik remote the system. these our plan approval will in in exclusive and sales, technician completed Switzerland quarter, Germany distributor will as for Biotronik and handover focusing in mapper first accounts countries existing an the training have countries. executed on
granted received working In in are approval Australia to and Biotronik on had Acutus Malaysia. Acutus in actively Mark countries. and was products CE approvals access for related in already regulatory system our accessory other concert regulatory addition mapping clearance Biotronik obtained, and in the special
with pleased very knowledge. be learning we encouraged strong with local see distance and and to teams related to as for case heavily continue from relationship hardware, catheters on software, rely are our engagement Biotronik We our
commercial-grade heart have we development technology. energy contact here and development On of mapping in out on innovation pace software progress scope access the post-field releasing product and building of made suite, ablation on product is our our left the at lines Acutus our addition front, impressive. of major really the The to
field we features or ablation, of and example conventional products, contact or like. conventional full mapping an our noncontact the RF of July it X, be multiple crossing, ablation, one of scale product and septal elements testing portfolio, conducted XX since efforts, have As pulsed our the new each preclinical labs
faster U.S. Moving mapping core on is meaningful In as clearance enhanced AcQMap including key handling regulatory catheter evolution X.X. a and noncontact updates. a This third production on now we quarter with important and on product of capabilities, the times. an to catheter it reduction our clinical our combines cost XXXX, advantages received acquisition
market begun release the initial limited and of positive. feedback is Our catheter has
Our catheter clinical lines. to have IDE and been the through working therapy our X teams regulatory also studies for diligently process separate initiate
gold-tipped irrigated to expected XXXX. half the for first plan our separate we Both force sensing market, AcQBlate now commence radiofrequency catheters. of submit U.S. are the trials For X to in ablation
As technology devices we related systemic driven contract have by largely you to of companies, ethylene community with regional local seen may seen concerns. other environmental oxide, medical medical challenges with have sterilization sterilizer
vendors to commence as the by issues, sterilization challenging. these of attempting IDE as can with pandemic, validations As be ours, new products, for exacerbated cope completion such trials
As a as are pushed compared result, lines. dates start expecting IDE X our be time out quarter roughly we currently trial to previous to
on The commercially which trials, XXXX seeking indication, approved right available take approval years first is expect our lines, a time to flutter expected in to a current indication we or atrial complete X early to obtain of about and PMA. Based and is XXXX. that or premarket be late
premarket take obtain persistent approximately approval, enter or the in fibrillation means paroxysmal XXXX. years a the and U.S. we early to will complete expect late market XXXX seeking currently atrial which to market indication in and is X likely U.S. Second potentially and
U.S. versions take we Acutus and expect approval first of Mark and a involves of X.X partnership series XXXX in which receive the years trial platinum-iridium approximately complete, catheters, relates labeled third CE U.S. to to half ablation Biotronik-sourced private The Biotronik the around with our which premarket and should markets. means of gold-tipped to
and CE-governed be ablation ahead, on bringing the irrigated to Looking we within This the catheter weeks. milestone our accessories markets. receiving force are to an sensing AcQBlate company. novel looking force ablation will anticipate we forward CE And this for coming mark gold-tipped, radiofrequency catheter important related sensing
in our strategy, I the you our growth for our installed business. our of and growth revenue of growth A like consoles. picture on is for longer-term installed today to base revenue razor grow over the It is time. plans foundational major razorblades. to would in -- bigger our drivers sorry, -- of portfolio the focus remind side Growing expansion -- our to to AcQMap Turning of commercial is main the our our base
clinicians increased driving the consoles. on access, includes used of the catheters. expanding This by the focused also crossing our products Increased of disposable and both system. This into using of third driver, includes per types therapy, are We number the septal utilization range feeds our and performed various of diagnostic Acutus-supplied case. procedures utilization growth procedures mapping,
a field Vice of release electrophysiologist Steve was Finally, before regarding a Dr. founder part and Science pulsed the He team. our former CEO I saw of today a and Farapulse, to a I technologist our President background, over pioneer to Translational Gary, the in Notably, Officer. Mickelson in things an field the of is thrilled practicing is and highly prolific turn Steve him are press Acutus hope we with of the have as you hiring thought new he a and Chief clinical and leader as promising recognized field ablation. extensive inventor.
be to look opportunities program pulsed continue the calls. our about progress and and We on very ablation field possibilities forward excited updating for on you to future our
financial to it turn now over I'll results. Gary that, With Gary? for our
